» Articles » PMID: 38397838

Mitochondria Dysfunction and Neuroinflammation in Neurodegeneration: Who Comes First?

Overview
Date 2024 Feb 24
PMID 38397838
Authors
Affiliations
Soon will be listed here.
Abstract

Neurodegenerative diseases (NDs) encompass an assorted array of disorders such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis, each characterised by distinct clinical manifestations and underlying pathological mechanisms. While some cases have a genetic basis, many NDs occur sporadically. Despite their differences, these diseases commonly feature chronic neuroinflammation as a hallmark. Consensus has recently been reached on the possibility that mitochondria dysfunction and protein aggregation can mutually contribute to the activation of neuroinflammatory response and thus to the onset and progression of these disorders. In the present review, we discuss the contribution of mitochondria dysfunction and neuroinflammation to the aetiology and progression of NDs, highlighting the possibility that new potential therapeutic targets can be identified to tackle neurodegenerative processes and alleviate the progression of these pathologies.

Citing Articles

The Potential of cfDNA as Biomarker: Opportunities and Challenges for Neurodegenerative Diseases.

Aydin S, Ozdemir S, Adiguzel A J Mol Neurosci. 2025; 75(1):34.

PMID: 40080233 PMC: 11906534. DOI: 10.1007/s12031-025-02317-8.


Mitochondrial Dysfunction in Neurodegenerative Diseases.

Yang H Cells. 2025; 14(4).

PMID: 39996748 PMC: 11853439. DOI: 10.3390/cells14040276.


Newer Therapeutic Approaches in Treating Alzheimer's Disease: A Comprehensive Review.

Reddi Sree R, Kalyan M, Anand N, Mani S, Gorantla V, Sakharkar M ACS Omega. 2025; 10(6):5148-5171.

PMID: 39989768 PMC: 11840625. DOI: 10.1021/acsomega.4c05527.


Alzheimer's Disease: Exploring Pathophysiological Hypotheses and the Role of Machine Learning in Drug Discovery.

Dominguez-Gortaire J, Ruiz A, Porto-Pazos A, Rodriguez-Yanez S, Cedron F Int J Mol Sci. 2025; 26(3).

PMID: 39940772 PMC: 11816687. DOI: 10.3390/ijms26031004.


Astaxanthin-loaded brain-permeable liposomes for Parkinson's disease treatment via antioxidant and anti-inflammatory responses.

Nguyen T, Khanal S, Lee E, Choi J, Bohara G, Rimal N J Nanobiotechnology. 2025; 23(1):78.

PMID: 39905399 PMC: 11792324. DOI: 10.1186/s12951-025-03104-8.


References
1.
Onyango I, Jauregui G, carna M, Bennett Jr J, Stokin G . Neuroinflammation in Alzheimer's Disease. Biomedicines. 2021; 9(5). PMC: 8150909. DOI: 10.3390/biomedicines9050524. View

2.
Pratico D, Uryu K, Leight S, Trojanoswki J, Lee V . Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J Neurosci. 2001; 21(12):4183-7. PMC: 6762743. View

3.
Deora V, Lee J, Albornoz E, McAlary L, Jagaraj C, Robertson A . The microglial NLRP3 inflammasome is activated by amyotrophic lateral sclerosis proteins. Glia. 2019; 68(2):407-421. DOI: 10.1002/glia.23728. View

4.
Klemann C, Martens G, Sharma M, Martens M, Isacson O, Gasser T . Integrated molecular landscape of Parkinson's disease. NPJ Parkinsons Dis. 2017; 3:14. PMC: 5460267. DOI: 10.1038/s41531-017-0015-3. View

5.
Cherian A, Divya K . Genetics of Parkinson's disease. Acta Neurol Belg. 2020; 120(6):1297-1305. DOI: 10.1007/s13760-020-01473-5. View